12:24 PM EST, 03/07/2024 (MT Newswires) -- Natera ( NTRA ) said Thursday that its Prospera blood test used to evaluate the risk of organ rejection in heart and kidney transplant patients is now covered by insurance provided by "one of the largest Blue Cross Blue Shield plans in the US."

The coverage policy includes serial testing to assess graft status and identify the risk of rejection, the company said, without identifying the insurer.

Commercially insured patients have historically had limited access to donor-derived cell-free DNA-based testing although the tests have become popular as a way to indicate which patients may reject organs following transplants, the company said.

Natera ( NTRA ) shares were up 0.5% in midday trading, easing from a nearly 2% advance earlier Thursday to a new 52-week high of $91.80 a share.

Price: 90.37, Change: +0.14, Percent Change: +0.16